Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

224
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
224
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

189
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
189
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

184
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
184
Routh-Hurwitz Criterion II01:19

Routh-Hurwitz Criterion II

614
In the application of the Routh-Hurwitz criterion, two specific scenarios can arise that complicate stability analysis.
The first scenario occurs when a singular zero appears in the first column of the Routh table. This situation creates a division by zero issues. To resolve this, a small positive or negative number, denoted as epsilon (∈), is substituted for the zero. The stability analysis proceeds by assuming a sign for ∈. If ∈ is positive, any sign change in the first...
614
Routh-Hurwitz Criterion I01:15

Routh-Hurwitz Criterion I

406
Consider an electrical power grid, where stability is essential to prevent blackouts. The Routh-Hurwitz criterion is a valuable tool for assessing system stability under varying load conditions or faults. By analyzing the closed-loop transfer function, the Routh-Hurwitz criterion helps determine whether the system remains stable.
To apply the Routh-Hurwitz criterion, a Routh table is constructed. The table's rows are labeled with powers of the complex frequency variable s, starting from the...
406
Meiosis I01:49

Meiosis I

200.5K
Meiosis is a carefully orchestrated set of cell divisions, the goal of which—in humans—is to produce haploid sperm or eggs, each containing half the number of chromosomes present in somatic cells elsewhere in the body. Meiosis I is the first such division, and involves several key steps, among them: condensation of replicated chromosomes in diploid cells; the pairing of homologous chromosomes and their exchange of information; and finally, the separation of homologous chromosomes by...
200.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.

Blood advances·2026
Same author

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

Nature immunology·2026
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Blood·2026
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.1K

Richter Syndrome.

Adalgisa Condoluci1,2, Davide Rossi3,4

  • 1Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Current Oncology Reports
|February 13, 2021
PubMed
Summary
This summary is machine-generated.

Richter syndrome (RS), an aggressive form of chronic lymphocytic leukemia, has poor outcomes. Combining chemo-immunotherapy with novel agents shows promise, but less toxic options are needed for frail patients.

Keywords:
CLLDLBCLHodgkin lymphomaRichter syndromeTransformation

More Related Videos

Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers
09:16

Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers

Published on: March 14, 2018

10.5K
A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.1K

Related Experiment Videos

Last Updated: Nov 17, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.1K
Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers
09:16

Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers

Published on: March 14, 2018

10.5K
A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.1K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Richter syndrome (RS) represents an aggressive transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • RS presents a significant unmet clinical need within CLL management due to its poor patient outcomes.
  • Recent biological insights into RS pathogenesis support the exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review the key disease characteristics of Richter syndrome.
  • To summarize the current therapeutic options available for managing RS.
  • To highlight the need for improved treatment paradigms for RS patients.

Main Methods:

  • Literature review of disease characteristics.
  • Analysis of current therapeutic approaches for RS.
  • Discussion of emerging preclinical models and targeted combinations.

Main Results:

  • Monotherapy with novel agents has demonstrated limited impact on survival in RS.
  • Combination chemo-immunotherapy with novel agents has shown improved outcomes, indicating synergistic effects.
  • Patient frailty necessitates less toxic management strategies, often leaving limited therapeutic choices.

Conclusions:

  • Treatment options for Richter syndrome remain limited and require expansion.
  • Further research into actionable pathways and targeted drug combinations is crucial.
  • Developing less toxic, effective therapies is essential for improving RS patient prognosis.